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Summary ‘‘Evidence-based medicine (EBM)’’ implies effective and high qual-
ity practice for patients based on well-grounded medical science. The success of
clinical trials in Japan is essential to build original evidence speciﬁc for Japanese
patients. Based on this concept, we have performed several large-scale clinical tri-
als to provide EBM, including the Japanese Antiplatelets Myocardial Infarction Study
[JAMIS; clinical improvement in acute myocardial infarction (AMI) patients with
antiplatelet therapy], the Japanese -Blockers and Calcium Antagonists Myocardial
Infarction (JBCMI; comparison of the effects of -blockers and calcium antagonists on
cardiovascular events in post-AMI patients), a multicenter study for aggressive lipid-
lowering strategy by HMG-CoA reductase inhibitors in patients with AMI (MUSASHI;
effects of statin therapy on cardiovascular events in patients with AMI), and the
Japanese Primary Prevention of Atherosclerosis with Aspirin for Diabetes (JPAD trial;
efﬁcacy of low-dose aspirin therapy for primary prevention of atherosclerotic events
in type 2 diabetic patients). The results of these prospective studies were directly
linked with clinical practice. We have acquired the know-how of large-scale clinical
trials; an important point is to have passion for ‘‘buildup evidence speciﬁc for the
Japanese’’ and to recruit subjects for enrollment after explaining the signiﬁcance
of ‘‘clinical trials for the Japanese’’.
© 2009 Japanese College of Cardiology. Published by Elsevier Ireland Ltd. All rights
reserved.
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Introduction
‘‘Evidence-based medicine (EBM)’’ implies provid-
ing effective and high quality clinical practice for
patients based on well-grounded medical science.
Our group has completed several large-scale clini-
cal trials to provide EBM. In Japan, evidence-based
guidelines for the management of cardiovascular
disease were previously prepared, however, such
guidelines cited mainly work that originated in
western countries. There is no doubt that the west-
ern data cannot be applied blindly to different
ethnic groups with heart disease. Therefore, evi-
dence for Japanese is required for the clinical
setting. In the past several years, the strategy used
for the treatment of heart disease has been chang-
ing constantly based on well-established large-scale
clinical trials that were performed mainly in west-
ern countries. Recent years have witnessed the
birth of Japanese clinical trials and the results have
been published gradually.
In this article, we summarize and review several
prospective clinical trials including the latest ones
from our group on cardiovascular diseases.
Prospective randomized clinical trials
with regard to secondary prevention of
acute myocardial infarction
It is well known that the Japanese population has
lower mortality from coronary artery disease com-
pared with western countries [1]. This difference
between Japanese and Caucasians may be due to
racial or ethnic differences in the response to drugs,
probably related to differences in the distribution
of polymorphisms of drug-metabolizing enzymes,
a
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o................................................... 180
................................................... 181
rug receptors, and environmental factors [2—4].
owever, well-established medical strategies were
ot available in the past for the secondary pre-
ention of acute myocardial infarction (AMI) in
apanese patients. Therefore, prospective ran-
omized clinical trials are indispensable for the
reparation of guidelines in the Japanese clinical
etting.
igniﬁcance of antiplatelet therapy in
apanese AMI patients: the Japanese
ntiplatelets Myocardial Infarction Study
JAMIS)
he multicenter study, the Japanese Antiplatelets
yocardial Infarction Study (JAMIS) [5] was per-
ormed to determine the effects of aspirin or
rapidil on clinical outcome compared with no
ntiplatelet treatment in patients with AMI. The
AMIS was a multicenter open-label randomized
ontrolled trial of aspirin 81mg/day, trapidil
00mg/day, and no antiplatelet treatment in
atients with AMI admitted within 1 month from
he onset of symptoms. The study patients were
ecruited from 70 hospitals in 18 prefectures
rom October 1994 to March 1996. The primary
bjective was to compare the effect of these
hree regimens on cardiovascular events, such
s cardiovascular death (including sudden death),
einfarction, uncontrolled unstable angina requir-
ng admission to hospital, and nonfatal ischemic
troke. A total of 723 patients were randomly172 H. Ogawa, S. Kojima
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Low-dose aspirin for primary prevention of atherosclerotic events in patients with diabetes mellitus:ssigned to the aspirin group (n = 250), trapidil
roup (n = 243) and control group (n = 230). There
ere no signiﬁcant differences among the three
roups with respect to age, gender, time from
nset to admission, the frequency of performed
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Figure 1 (A) Kaplan—Meier plot of reinfarction observed in the aspirin and control groups. (B) Kaplan—Meier plot of
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mergency coronary angiography, index AMI loca-
ion, types of Q-wave AMI and non-Q-wave AMI,
nd the frequency of previous myocardial infarc-
ion. The frequencies of reperfusion therapy, such
s thrombolysis, percutaneous transluminal coro-
ary angioplasty (PTCA), and thrombolysis and
TCA, and that of other medications (nitrates,
alcium antagonists, -blockers, and angiotensin-
onverting-enzyme inhibitors) were also distributed
qually among the three groups. Follow-up data
ere available for 100% of the patients at 3 months
nd 98.2% at the end of the study period. Thir-
een patients (1.8%) were lost to follow-up (2 in
he aspirin group, 5 in the trapidil group, and 6
n the control group). The mean follow-up period
as 475 days (1.3 years), and the maximum was
70 days. Reinfarction occurred in 5 patients of
he aspirin group, 9 of the trapidil group, and 17
f the control group. The relative risk of rein-
arction in the aspirin group compared with the
ontrol group was 0.271 (95% conﬁdence interval
CI] 0.101—0.722, p = 0.0045) (Fig. 1A), and that
or the trapidil group compared with the control
roup was 0.501 (95% CI 0.228—1.101, p = 0.0810)
Fig. 1B). The number of patients with cardiovas-
o
r
aKaplan—Meier plot of cardiovascular events observed in
diovascular events observed in the trapidil and control
ular death (aspirin group: 6; trapidil group: 4;
ontrol group: 5) and non-cardiac death (aspirin
roup: 3; trapidil group: 4; control group: 2) was
bout the same in the three groups. Cardiovascu-
ar events occurred in 36 patients of the aspirin
roup, 22 of the trapidil group, and 42 of the control
roup. The relative risk of developing cardiovas-
ular events in the aspirin group compared with
he control group was 0.789 (95% CI 0.525—1.185,
= 0.1961) (Fig. 1C). On the other hand, that for the
rapidil group compared with the control group was
.496 (95% CI 0.306—0.804, p = 0.0039) (Fig. 1D).
nalyses of the primary endpoints showed that the
ncidence of reinfarction was lower in the aspirin
roup compared with the control group and that
f cardiovascular events was lower in the trapidil
roup compared with the control group. Adverse
ffects were observed in the aspirin group (n = 7)
nd trapidil group (n = 16). These included minor
ide effects, which disappeared after discontinua-
ion of the drugs.
The JAMIS demonstrated that long-term daily use
f 81mg aspirin reduced the incidence of recur-
ent AMI compared with the group receiving no
ntiplatelets after AMI and that the incidence of
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cardiovascular events was reduced in the group
receiving 300mg trapidil daily compared with the
group receiving no antiplatelets.
Comparison between -blockers and
calcium antagonists in preventing
cardiovascular events in Japanese AMI
patients: the Japanese -Blockers and
Calcium Antagonists Myocardial Infarction
(JBCMI) Study
The Japanese -Blockers and Calcium Antagonists
Myocardial Infarction (JBCMI) Study compared the
effects of -blockers and calcium antagonists on
cardiovascular events in Japanese post-AMI patients
[6]. The study was a multicenter, open-label, con-
trolled, randomized clinical trial. A total of 1090
patients were consecutively enrolled at 90 hospi-
tals in 28 prefectures of Japan between December
1998 and October 2000. Patients were eligible for
the study if they presented within 1 month of the
onset of symptoms of AMI. Randomization was con-
ducted during ﬁrst day to 1 month after the attack.
Of these patients, 545 were randomized into the
-blocker group, and 545 into the calcium antag-
onist group. The -blockers administered were
atenolol, bisoprolol, calvedilol, and metoprolol.
Calcium antagonists were those of slow-release or
long-acting dihydropyridines including amlodipine,
manidipine, slow-release nifedipine, and nisoldip-
ine. The choice of the drugs of each class and
the dose were at the discretion of each attend-
ing physician. The primary endpoint was deﬁned as
the combination of cardiovascular death, nonfatal
reinfarction, uncontrolled unstable angina includ-
ing coronary spastic angina, and nonfatal stroke.
Thirty-one (5.7%) patients of the -blocker group
and 22 (4.0%) patients of the calcium antagonist
group were not treated with assigned therapy.
Sixty-four (11.8%) patients of the -blocker group
and 43 (7.9%) patients of the calcium antagonist
group discontinued therapy. On admission, 86% of
patients of the -blocker group and 89% of the
calcium antagonist group were classiﬁed as Kil-
lip class I. The rate of reperfusion therapies was
85.1% for the -blocker group and 80.6% for the
calcium antagonist group. PCI was performed in
77.6% and 75.5% of the -blocker group and the
calcium antagonist group, respectively. The rate of
revascularization with thrombolysis in myocardial
infarction (TIMI) grade 3 was 83.4% in the -blocker
group and 84.4% in the calcium antagonist group.
Almost all patients received aspirin (97.8% vs.
98.0%) and the administration rate of angiotensin-
converting-enzyme inhibitors (62.9% vs. 63.8%) was
s
s
m
d
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lso high. The period from onset of attack to enroll-
ent was 0—30 (median 13) days for the -blockers
roup and 0—30 (median 12) days for the calcium
ntagonists group. The average follow-up period
as 454± 274 days.
There was no signiﬁcant difference in the
rimary endpoint or total cardiovascular events
etween the -blocker group (14.3% [n = 78])
nd calcium antagonist group (13.2% [n = 72])
p = 0.349). There were no signiﬁcant differences in
he incidence of cardiovascular death (1.7% [n = 9]
s. 1.1% [n = 6], p = 0.377) (Fig. 2A), nonfatal infarc-
ion (0.9% [n = 5] vs. 1.3% [n = 7], p = 0.698) (Fig. 2B),
nstable angina (11.0% [n = 60] vs. 10.6% [n = 58],
= 0.572) (Fig. 2C), or nonfatal stroke (0.7% [n = 4]
s. 0.2% [n = 1], p = 0.148) (Fig. 2D) between the two
roups. However, the rates of occurrence of heart
ailure (4.2% [n = 23] vs. 1.1% [n = 6], p = 0.001)
Fig. 3A) and coronary spasm (1.3% [n = 7] vs. 0.2%
n = 1], p = 0.027) (Fig. 3B) were signiﬁcantly higher
n the -blocker blocker group than in the calcium
ntagonist group.
The JBCMI study found no signiﬁcant differences
n the incidence of cardiovascular events including
ardiac death, nonfatal AMI, uncontrolled unstable
ngina, and nonfatal stroke between the -blocker
roup and calcium antagonist group. Heart failure
ccurred earlier in the -blocker group probably
ecause the dose was not necessarily titrated.
ffectiveness of lipid-lowering therapy with
arly administration of statins in Japanese
MI patients: multicenter study for
ggressive lipid-lowering strategy by
MG-CoA reductase inhibitors in patients
ith AMI (MUSASHI-AMI)
he multicenter study for aggressive lipid-lowering
trategy by HMG-CoA reductase inhibitors in
atients with AMI (MUSASHI) investigated the
ffects of statin therapy on cardiovascular events
ncluding heart failure in Japanese AMI patients
ith ST elevation after percutaneous coronary
ntervention (PCI) [7]. Between February 2002 and
eptember 2004, 486 eligible consecutive patients
ith AMI who were admitted to 54 medical centers
n 28 prefectures of Japan were enrolled. Acute
hase reperfusion therapy included PCI and/or
hrombolysis after admission when needed. Study
atients were randomly assigned within 96 h after
ymptom onset with stratiﬁcation by center to the
tandard therapy, which included open-label treat-
ent with any of the statins available in Japan
uring the recruitment period (pravastatin, ator-
astatin, ﬂuvastatin, simvastatin, or pitavastatin),
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Figure 2 (A) Kaplan—Meier plot of cardiovascular death in the -blocker and calcium antagonist groups. (B)
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D) Kaplan—Meier plot of nonfatal stroke in the -blocker to the control group (standard AMI therapy with-
ut statins). Treating physicians were allowed to
hange the dosage of statin during the study period.
he primary endpoint was deﬁned as combination
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igure 3 (A) Kaplan—Meier plot of heart failure in the -bloc
lot of coronary spasm in the -blocker and calcium antagonig hospitalization in the -blocker and calcium antago-
arction in the -blocker and calcium antagonist groups.
calcium antagonist groups.f cardiovascular death, nonfatal AMI, recurrent
ymptomatic myocardial ischemia with objective
vidence and requiring emergency rehospitaliza-
ion, congestive heart failure requiring emergency
ker and calcium antagonist groups and (B) Kaplan—Meier
st groups.
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rehospitalization, and nonfatal stroke. Patients
were monitored for events during 24 months after
randomization.
A total of 486 patients were enrolled; 241 were
randomly assigned to receive discretional statins
and 245 to receive standard AMI therapy without
statins. Fatal complications such as left-ventricular
free wall rupture occurring within 7 days after
symptom onset were excluded from the analysis.
Demographic and clinical characteristics of sur-
vivors of acute-phase complications (from data
available for 237 patients of the statin and 244
of the non-statin group) were similar at base-
line. ST elevation was seen in about 90% of the
study patients and the two groups included sub-
stantial numbers of smokers. Coronary angioplasty
was selected as the reperfusion therapy in more
than 90% of those patients. Bare metal stents, but
not drug-eluting stents, were used in most patients
because the latter was not available in Japan at the
time of the study.
At the time of randomization, serum lipid lev-
els were nearly equal in both groups (Fig. 4A—D).
In all randomized patients, the mean total choles-
terol levels were 207mg/dL, low-density lipopro-
tein (LDL) cholesterol levels were 133mg/dL,
mean triglyceride levels were 134mg/dL, and
high-density lipoprotein cholesterol levels were
46mg/dL. In the statin group, total and LDL choles-
terol levels decreased by 13% and 24% by 6 months
m
e
t
(
Figure 4 Serum lipid levels in statin vs. non-statin groups.
lipoprotein cholesterol (B), high-density lipoprotein choleste
*p < 0.05. HDL, high-density lipoprotein; LDL, low-density lipoH. Ogawa, S. Kojima
fter randomization, 14% and 27% by 1 year, and
7% and 25% by 2 years, respectively. In contrast,
n the non-statin group, total and LDL cholesterol
evels decreased by 1% and 4% by 6 months, 1% and
% by 1 year, and 3% and 8% by 2 years, respectively.
During the follow-up period, primary endpoint
vents occurred in 15 patients (5.9%) of the statin
roup (2 cardiovascular death, 3 nonfatal acute
yocardial infarction, 6 symptomatic myocardial
schemia requiring emergency rehospitalization, 1
eart failure requiring urgent rehospitalization,
nd 3 stroke) and 29 (11.9%) of the non-statin
roup (1 cardiovascular death, 17 symptomatic
yocardial ischemia requiring emergency rehos-
italization, 9 heart failure requiring urgent
ehospitalization, and 2 stroke), with an absolute
ifference of 5.2%. Statin treatment signiﬁcantly
educed the risk of the primary combined endpoints
uring a mean follow-up period of 416± 11 days
Fig. 5A). There were no signiﬁcant differences in
isk of death, nonfatal AMI, and stroke between the
tatin and non-statin groups. In contrast, the statin
roup had a lower risk of congestive heart fail-
re requiring urgent rehospitalization. The effect of
tatins in preventing heart failure became evident
t 6 months after randomization (Fig. 5B). Further-
ore, symptomatic myocardial ischemia requiring
mergency rehospitalization was more frequent in
he statin group compared to the non-statin group
Fig. 5C).
Data are mean value. Total cholesterol (A), low-density
rol (C), and triglycerides (D). ***p < 0.0001, **p < 0.001,
protein.
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aigure 5 (A) Kaplan—Meier estimates of combined prima
ailure. (C) Kaplan—Meier estimates of unstable angina.
The MUSASHI-AMI trial demonstrated that a
ipid-lowering strategy with statins decreased
ubsequent cardiovascular events, in particular,
ongestive heart failure and unstable angina in
apanese patients with AMI.
ovel strategies for primary prevention
f atherosclerotic events in patients
ith diabetes mellitus
atients with diabetes are at high risk of fatal
nd nonfatal macrovascular events. The risk of
yocardial infarction in diabetic patients with-
ut previous myocardial infarction is as high as
or nondiabetic patients with previous myocar-
ial infarction [8]. The Kumamoto study indicated
hat intensive glycemic control by multiple insulin
njection therapy can delay the onset and pro-
ression of diabetic retinopathy, nephropathy,
nd neuropathy [9]. On the other hand, the
K Prospective Diabetes Study reported that
ntensive blood-glucose control with sulfonylureas
r insulin substantially reduced the risk of
icrovascular complications but not macrovas-
ular disease [10]. Therefore, novel medical
reatment in addition to anti-diabetic agents is
mportant to prevent the development and pro-
ression of cardiovascular complications in diabetic
atients.
p
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f
ndpoints. (B) Kaplan—Meier estimates of congestive heart
ow-dose aspirin for primary prevention of
therosclerotic events in patients with
iabetes mellitus: the Japanese Primary
revention of Atherosclerosis with Aspirin
or Diabetes (JPAD) Study
he Japanese Primary Prevention of Atheroscle-
osis with Aspirin for Diabetes (JPAD) trial was
ndertaken to examine the efﬁcacy of low-dose
spirin therapy for the primary prevention of
therosclerotic events in type 2 diabetic patients
11]. This multicenter, prospective, randomized,
pen-label blinded-endpoint study was conducted
rom December 2002 through April 2008 in 163
nstitutions throughout Japan. The study screened
567 type 2 diabetic patients without history of
therosclerotic disease, including cardiovascular
isease, stroke, and peripheral vascular disease. Six
atients who withdrew their informed consent were
xcluded. Twenty-two patients met the exclusion
riteria (10 with history of atherosclerotic disease,
0 aged >85 years, 1 no diabetes, and 1 receiving
arfarin). A total of 2539 patients were ran-
omly assigned into the following two groups: 1262
atients in the aspirin group (81 or 100mg/day)
nd 1277 patients in the non-aspirin group. The
rimary endpoint was any atherosclerotic event,
hich was a composite of sudden death, death
rom coronary, cerebrovascular, and aortic causes,
onfatal acute myocardial infarction, unstable
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angina, newly developed exertional angina, non-
fatal ischemic and hemorrhagic stroke, transient
ischemic attack, or nonfatal aortic and peripheral
vascular disease (arteriosclerosis obliterans, aortic
dissection, mesenteric arterial thrombosis) during
the follow-up period. Key secondary endpoints were
each and combinations of primary endpoints and
death from any cause. Further, adverse events ana-
lyzed in that study included gastrointestinal (GI)
events and any hemorrhagic events other than hem-
orrhagic stroke. The median follow-up period was
4.37 years. A total of 193 patients were lost to
follow-up, and data for those patients were cen-
sored at the day of last follow-up.
All baseline clinical characteristics including
treatments for diabetes, hypertension, and dyslipi-
demia, and diabetic microvascular complications,
were similar between the two groups. The mean
age of the whole group was 65± 10 years and
55% of the patients were men. The median his-
tory of diabetes was 7.3 years in the aspirin group
and 6.7 years in the non-aspirin group. Diabetes
was well controlled in both arms: glycosylated
hemoglobin level was 7.1± 1.4% in the aspirin arm
and 7.0± 1.2% in the non-aspirin arm. The preva-
lence of hypertension and dyslipidemia in the entire
population was 58% and 53%, respectively. The sys-
tolic/diastolic blood pressure was well controlled
in both arms: 136± 15/77± 9mmHg in the aspirin
arm and 134± 15/76± 9mmHg in the non-aspirin
arm.
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Figure 6 (A) Kaplan—Meier estimates of primary endpoint
estimates of combined endpoint of fatal coronary and fatal cH. Ogawa, S. Kojima
A total of 154 atherosclerotic events occurred in
hat study. The incidence of the primary endpoint
f any atherosclerotic event, a composite of sudden
eath, death from cardiovascular or aortic causes,
onfatal acute myocardial infarction, unstable
ngina, exertional angina, nonfatal ischemic and
emorrhagic stroke, transient ischemic attack,
r nonfatal aortic and peripheral vascular dis-
ase (arteriosclerosis obliterans, aortic dissection,
esenteric arterial thrombosis) was not signiﬁ-
antly different in the aspirin group (68 events, 5%)
han the non-aspirin group (86 events, 7%) [hazard
atio (HR), 0.80; 95% CI, 0.58—1.10; log-rank test,
= 0.16] (Fig. 6A). The combined fatal coronary
vents and fatal cerebrovascular events occurred
n 1 (stroke) patient in the aspirin group and 10
atients (5 fatal MI and 5 fatal stroke) in the non-
spirin group for a 90% relative risk reduction (HR,
.10; 95% CI, 0.01—0.79, p = 0.004) (Fig. 6B). Other
econdary coronary, cerebrovascular, and periph-
ral vascular disease endpoints are listed in Table 1;
here were no signiﬁcant differences between the
spirin and the non-aspirin arms in these endpoints.
here was no signiﬁcant difference in cardiovascu-
ar mortality; two deaths due to aortic dissection
ere recorded in the low-dose aspirin arm. Hem-
rrhagic strokes occurred in 13; the incidences in
ach group were similar (6 in the aspirin group
nd 7 in the non-aspirin group). One fatal hemor-
hagic stroke was recorded in the aspirin group and
in the non-aspirin group. Death from any cause
of total atherosclerotic events and (B) Kaplan—Meier
erebrovascular events. CI, conﬁdence interval.
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rigure 7 Kaplan—Meier estimates of total atheroscle-
otic events in patients 65 years of age or older. CI,
onﬁdence interval.
ccurred in 34 patients of the aspirin group and 38
atients of the non-aspirin group (HR, 0.904; 95%
I, 0.569—1.1436; log-rank test, p = 0.668).
In the 1363 patients aged ≥65 years (719 in the
spirin group and 644 in the non-aspirin group),
he incidence of atherosclerotic events was sig-
iﬁcantly lower in the aspirin group (45 events,
%) than in the non-aspirin group (59 events, 9%)
HR, 0.68; 95% CI, 0.46—0.99, p = 0.047) (Fig. 7). In
he 1176 patients <65 years of age, the incidence
f atherosclerotic events was not signiﬁcantly dif-
erent between the aspirin group (23; 4%) and
he non-aspirin group (27; 4%) (HR, 1.0; 95% CI,
.57—1.70, p = 0.98). Interaction with age was not
igniﬁcant (p = 0.27). There were no signiﬁcant dif-
erences between the aspirin group and non-aspirin
roup in other subgroup analyses, as shown in
ig. 8: including men, women, hypertensive, nor-
otensive, current or past smoker, nonsmoker, and
yslipidemia, and normolipidemia.
The hemorrhagic events consisted of GI bleed-
ng in 12 patients of the aspirin group and 4 of
he non-aspirin group, and retinal hemorrhage in
patients of the aspirin group and 4 of the non-
spirin group. In the aspirin group, there were
patients who developed serious adverse events
hat needed blood transfusion; while none of the
atients of the non-aspirin group required transfu-
ion. Another 13 patients of the aspirin group had
inor bleeding. There was no signiﬁcant difference
n the composite of hemorrhagic stroke and severe
I bleeding, which occurred in 10 patients of the
spirin group and in 7 patients of the non-aspirin
roup.
In summary, in the JPAD trial, the ﬁrst prospec-
ively designed trial to evaluate the effects of
ow-dose aspirin in type 2 diabetic patients free
f cardiovascular disease, showed that low-dose
spirin as primary prevention does not reduce the
isk of cardiovascular events. Aspirin was well tol-
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AFigure 8 Subgroup analysis of incidence of
erated in these patients, as there was no increase
in hemorrhagic stroke and only a small increase
in serious GI hemorrhagic events. These ﬁndings
should be interpreted in concert with the low inci-
dence of atherosclerotic disease in Japan and the
current management practice for cardiovascular
risk factors, and further studies of larger popula-
tion are warranted to conﬁrm the effects of aspirin
in primary prevention of cardiovascular disease in
diabetics [12].
Conclusions
The success of clinical trials in Japan is essential to
build evidence based on Japanese populations. The
above-mentioned trials were successful and sev-
eral clinical trials are currently underway. These
include candesartan for prevention of cardiovascu-
lar events after Cypher or Taxus coronary stenting
trial (4C), valsartan in cardiovascular disease with
renal dysfunction (V-CARD) study, and olmesartan
and calcium antagonists randomized (OSCAR) study.
The latter showed satisfactory prognosis after lipid-
lowering therapy consisting of early administration
of statins in Japanese patients with coronary heart
disease and diabetes mellitus, representing a sub-
analysis of the MUSASHI (MUSASHI-DM) [13] study,
a prospective observational study in patients with
AMI (New Japanese acute coronary syndrome study
[JACSS]). We have the know-how of large-scale clin-
ical trials acquired empirically to date. First of
all, a sense of purpose regarding clinical trials,
understanding of study protocol, and elucidation of
T
s
c
orosclerotic events. CI, conﬁdence interval.
etails of trials are very important before recruit-
ent of large numbers of participants across Japan.
ood mutual communication between participants
nd the regional research ofﬁce is indispensable. As
or surveys, a great number of headings should be
voided and the form of registration should be sim-
le yet accurate. A study conference should be held
eriodically and the state of registration and the
rials still in progress should be presented to partic-
pants. We also make every effort to increase the
otivation of participants. We provide incentives
o participants such as the chance of presentation
f common data. To put it concretely, JACSS data
ere analyzed and presented in national and inter-
ational scientiﬁc meetings by each participant
nd a total of 13 articles [14—26] have been pub-
ished so far. Moreover, it is essential that the chief
esearcher has accurate grasp of the entire oper-
tion including all participating institutions and is
lose to the participants. This is a part of the
eason why clinical trials are going well. In conclu-
ion, the most important point for researchers is to
ave passion for ‘‘buildup evidence speciﬁc for the
apanese’’ and to recruit subjects for enrollment
fter explaining the signiﬁcance of ‘‘clinical trials
or the Japanese’’.
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